isoproterenol has been researched along with Muscular Dystrophy, Duchenne in 10 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
Muscular Dystrophy, Duchenne: An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Electrocardiography on isoproterenol challenged mice showed that both models developed arrhythmias and died within 24 hours, while wild-type mice were free of pathology." | 7.81 | Selective Connexin43 Inhibition Prevents Isoproterenol-Induced Arrhythmias and Lethality in Muscular Dystrophy Mice. ( Contreras, JE; Fraidenraich, D; Gonzalez, JP; Ramachandran, J; Xie, LH, 2015) |
| " Electrocardiography on isoproterenol challenged mice showed that both models developed arrhythmias and died within 24 hours, while wild-type mice were free of pathology." | 3.81 | Selective Connexin43 Inhibition Prevents Isoproterenol-Induced Arrhythmias and Lethality in Muscular Dystrophy Mice. ( Contreras, JE; Fraidenraich, D; Gonzalez, JP; Ramachandran, J; Xie, LH, 2015) |
| "Patients with Duchenne muscular dystrophy (DMD) commonly present with severe ventricular arrhythmias that contribute to heart failure." | 1.51 | S-nitrosylation of connexin43 hemichannels elicits cardiac stress-induced arrhythmias in Duchenne muscular dystrophy mice. ( Contreras, JE; Fraidenraich, D; Himelman, E; Lillo, MA; Shirokova, N; Xie, LH, 2019) |
| "Duchenne muscular dystrophy is a fatal cardiac and skeletal muscle disease resulting from mutations in the dystrophin gene." | 1.42 | Sarcospan Regulates Cardiac Isoproterenol Response and Prevents Duchenne Muscular Dystrophy-Associated Cardiomyopathy. ( Crosbie-Watson, RH; Jordan, MC; Marshall, JL; Nguyen, RT; Parvatiyar, MS; Richardson, VA; Roos, KP, 2015) |
| "Cardiomyopathy in Duchenne muscular dystrophy (DMD) is an increasing cause of death in patients." | 1.37 | Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. ( Guerron, AD; Hoffman, EP; Nagaraju, K; Sali, A; Spurney, CF; van der Meulen, JH; Yu, Q, 2011) |
| "Nearly universal cardiomyopathy in Duchenne muscular dystrophy (DMD) contributes to heart failure and death." | 1.37 | Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice. ( Canan, BD; Chimanji, NS; Delfín, DA; Ganguly, R; Janssen, PM; Martin, CD; Mays, TA; Murray, JD; Rafael-Fortney, JA; Raman, SV; Schill, KE; Stangland, JE; Tran, T; Xu, Y, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lillo, MA | 1 |
| Himelman, E | 1 |
| Shirokova, N | 1 |
| Xie, LH | 2 |
| Fraidenraich, D | 2 |
| Contreras, JE | 2 |
| Sullivan, RT | 1 |
| Lam, NT | 1 |
| Haberman, M | 1 |
| Beatka, MJ | 1 |
| Afzal, MZ | 1 |
| Lawlor, MW | 1 |
| Strande, JL | 1 |
| Caluori, G | 1 |
| Pribyl, J | 1 |
| Pesl, M | 1 |
| Jelinkova, S | 1 |
| Rotrekl, V | 1 |
| Skladal, P | 1 |
| Raiteri, R | 1 |
| Meyers, TA | 1 |
| Heitzman, JA | 1 |
| Krebsbach, AM | 1 |
| Aufdembrink, LM | 1 |
| Hughes, R | 1 |
| Bartolomucci, A | 1 |
| Townsend, D | 1 |
| Li, Y | 1 |
| Zhang, S | 1 |
| Zhang, X | 1 |
| Li, J | 1 |
| Ai, X | 1 |
| Zhang, L | 1 |
| Yu, D | 1 |
| Ge, S | 1 |
| Peng, Y | 1 |
| Chen, X | 1 |
| Gonzalez, JP | 1 |
| Ramachandran, J | 1 |
| Parvatiyar, MS | 1 |
| Marshall, JL | 1 |
| Nguyen, RT | 1 |
| Jordan, MC | 1 |
| Richardson, VA | 1 |
| Roos, KP | 1 |
| Crosbie-Watson, RH | 1 |
| Spurney, CF | 1 |
| Guerron, AD | 1 |
| Yu, Q | 1 |
| Sali, A | 1 |
| van der Meulen, JH | 1 |
| Hoffman, EP | 1 |
| Nagaraju, K | 1 |
| Rafael-Fortney, JA | 1 |
| Chimanji, NS | 1 |
| Schill, KE | 1 |
| Martin, CD | 1 |
| Murray, JD | 1 |
| Ganguly, R | 1 |
| Stangland, JE | 1 |
| Tran, T | 1 |
| Xu, Y | 1 |
| Canan, BD | 1 |
| Mays, TA | 1 |
| Delfín, DA | 1 |
| Janssen, PM | 1 |
| Raman, SV | 1 |
| Yue, Y | 1 |
| Skimming, JW | 1 |
| Liu, M | 1 |
| Strawn, T | 1 |
| Duan, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Open Label Trial of Spironolactone Versus Prednisolone in Corticosteroid-naïve Boys With DMD[NCT03777319] | Phase 1 | 2 participants (Actual) | Interventional | 2018-12-05 | Terminated (stopped due to Inability to recruit participants.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The determination of whether spironolactone has similar efficacy to glucocorticoids in improving muscle strength in steroid naïve DMD patients. This will be determined by measuring the time to complete a 100 meter timed test (100M). (NCT03777319)
Timeframe: 6 months
| Intervention | sec (Number) |
|---|---|
| Spironolactone | -0.6 |
| Prednisolone | -5.3 |
Secondary outcome measures will be Dynamometry score, which is a summation of maximum voluntary isometric contraction test values for knee flexion, knee extension, elbow flexion, and elbow extension (NCT03777319)
Timeframe: 6 months
| Intervention | kg (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Elbow Flexion (Right)-Baseline | Elbow Flexion (Left)-Baseline | Elbow Extension (Right)-Baseline | Elbow Extension (Left)-Baseline | Knee Flexion (Right)-Baseline | Knee Flexion (Left)-Baseline | Knee Extension (Right)-Baseline | Knee Extension (Left)-Baseline | Elbow Flexion (Right)-Month 6 | Elbow Flexion (Left)-Month 6 | Elbow Extension (Right)-Month 6 | Elbow Extension (Left)-Month 6 | Knee Flexion (Right)-Month 6 | Knee Flexion (Left)-Month 6 | Knee Extension (Right)-Month 6 | Knee Extension (Left)-Month 6 | |
| Prednisolone | 3.6 | 4.1 | 5.3 | 4.1 | 3.3 | 3.4 | 4.8 | 5.2 | 2.9 | 3.4 | 4.3 | 3.8 | 4.1 | 3.9 | 6 | 5.1 |
| Spironolactone | 0 | 0 | 0 | 0 | 4.1 | 2.8 | 3.8 | 5.9 | 3.1 | 3.5 | 2.4 | 2.5 | 4.3 | 4.1 | 7.2 | 8.3 |
Electrolytes (Sodium, Potassium, Cloride and Carbon dioxide, mmol/L) will be measured on a monthly basis following initiation of either spironolactone or prednisolone. (NCT03777319)
Timeframe: 6 months
| Intervention | mmol/L (Number) | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sodium-Baseline | Sodium-Month 1 | Sodium-Month 2 | Sodium-Month 3 | Sodium-Month 4 | Sodium-Month 5 | Sodium-Month 6 | Potassium-Baseline | Potassium-Month 1 | Potassium-Month 2 | Potassium-Month 3 | Potassium-Month 4 | Potassium-Month 5 | Potassium-Month 6 | Chloride-Baseline | Chloride-Month 1 | Chloride-Month 2 | Chloride-Month 3 | Chloride-Month 4 | Chloride-Month 5 | Chloride-Month 6 | CO2-Baseline | CO2-Month 1 | CO2-Month 2 | CO2-Month 3 | CO2-Month 4 | CO2-Month 5 | CO2-Month 6 | |
| Prednisolone | 140 | 140 | 139 | 141 | 139 | 139 | 143 | 3.8 | 4 | 4.5 | 3.9 | 4.6 | 4.2 | 3.9 | 105 | 105 | 104 | 105 | 105 | 106 | 105 | 22 | 24 | 24 | 24 | 25 | 26 | 26 |
| Spironolactone | 142 | 142 | 141 | 142 | 139 | 139 | 140 | 4.5 | 4.7 | 4.2 | 4.1 | 4.5 | 4.5 | 4.3 | 103 | 109 | 107 | 103 | 103 | 103 | 101 | 29 | 22 | 25 | 27 | 28 | 28 | 26 |
10 other studies available for isoproterenol and Muscular Dystrophy, Duchenne
| Article | Year |
|---|---|
S-nitrosylation of connexin43 hemichannels elicits cardiac stress-induced arrhythmias in Duchenne muscular dystrophy mice.
Topics: Adrenergic beta-Agonists; Animals; Arrhythmias, Cardiac; Cell Membrane; Cell Membrane Permeability; | 2019 |
Cardioprotective effect of nicorandil on isoproterenol induced cardiomyopathy in the Mdx mouse model.
Topics: Animals; Cardiomyopathies; Disease Models, Animal; Female; Fibrosis; Isoproterenol; Mice, Inbred mdx | 2021 |
Non-invasive electromechanical cell-based biosensors for improved investigation of 3D cardiac models.
Topics: Biosensing Techniques; Cell Differentiation; Dystrophin; Fibroblasts; Humans; Induced Pluripotent St | 2019 |
Acute AT
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomyopathies; Dystrophin; Heart; Humans; Isopr | 2019 |
Blunted cardiac beta-adrenergic response as an early indication of cardiac dysfunction in Duchenne muscular dystrophy.
Topics: Adrenergic beta-Agonists; Age Factors; Animals; Calcium; Calcium Channels, L-Type; Calcium-Binding P | 2014 |
Selective Connexin43 Inhibition Prevents Isoproterenol-Induced Arrhythmias and Lethality in Muscular Dystrophy Mice.
Topics: Adolescent; Animals; Arrhythmias, Cardiac; Connexin 43; Disease Models, Animal; Female; Humans; Isop | 2015 |
Sarcospan Regulates Cardiac Isoproterenol Response and Prevents Duchenne Muscular Dystrophy-Associated Cardiomyopathy.
Topics: Animals; Cardiomyopathies; Carrier Proteins; Creatine Kinase, MB Form; Echocardiography; Fluorescent | 2015 |
Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.
Topics: Adrenergic beta-Agonists; Analysis of Variance; Animals; Aortic Valve; Blood Pressure; Body Weight; | 2011 |
Early treatment with lisinopril and spironolactone preserves cardiac and skeletal muscle in Duchenne muscular dystrophy mice.
Topics: Animals; Cardiac Imaging Techniques; Cardiomyopathies; Cardiotonic Agents; Disease Models, Animal; D | 2011 |
Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice.
Topics: Animals; Cardiomyopathies; Cardiotonic Agents; Dystrophin; Female; Genetic Therapy; Heterozygote; Is | 2004 |